Genmab A/S (NASDAQ:GMAB) Reaches New 1-Year Low – Here’s Why

Genmab A/S (NASDAQ:GMAB) reached a new 52-week low during mid-day trading on Monday . The company traded as low as $19.00 and last traded at $19.28, with a volume of 162448 shares. The stock had previously closed at $19.67.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on GMAB shares. HC Wainwright restated a “buy” rating and issued a $50.00 price target on shares of Genmab A/S in a research note on Thursday, January 23rd. Sanford C. Bernstein raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. BMO Capital Markets reiterated an “outperform” rating and issued a $48.00 price target (up from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. Finally, Redburn Atlantic started coverage on Genmab A/S in a report on Tuesday, October 8th. They set a “buy” rating on the stock. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $45.20.

Genmab A/S Stock Performance

The business has a 50 day simple moving average of $21.02 and a 200-day simple moving average of $23.67. The firm has a market cap of $12.72 billion, a price-to-earnings ratio of 18.66, a P/E/G ratio of 0.55 and a beta of 0.96.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.03). Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. The firm had revenue of $816.10 million for the quarter, compared to analysts’ expectations of $838.20 million. During the same period in the prior year, the company earned $0.47 EPS. As a group, research analysts anticipate that Genmab A/S will post 1.25 earnings per share for the current year.

Hedge Funds Weigh In On Genmab A/S

A number of large investors have recently bought and sold shares of the stock. GAMMA Investing LLC lifted its position in shares of Genmab A/S by 96.6% in the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock worth $45,000 after purchasing an additional 1,051 shares during the period. Cromwell Holdings LLC lifted its holdings in shares of Genmab A/S by 656.8% during the fourth quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock valued at $60,000 after purchasing an additional 2,496 shares in the last quarter. R Squared Ltd purchased a new stake in shares of Genmab A/S during the 4th quarter valued at about $93,000. Blue Trust Inc. grew its position in Genmab A/S by 892.0% in the 3rd quarter. Blue Trust Inc. now owns 4,315 shares of the company’s stock worth $108,000 after purchasing an additional 3,880 shares during the period. Finally, Allspring Global Investments Holdings LLC grew its holdings in shares of Genmab A/S by 43.6% in the third quarter. Allspring Global Investments Holdings LLC now owns 4,653 shares of the company’s stock worth $113,000 after acquiring an additional 1,413 shares during the period. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.